Miscellaneous immune disorders:
Indications for: RUZURGI
Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to <17yrs of age.
Adult Dosage:
Not applicable.
Children Dosage:
<6yrs: not established. 6–<17yrs: (≥45kg): initially 15–30mg daily in 2–3 divided doses, may increase daily by 5–10mg increments, divided in up to 5 doses; max single dose: 30mg; max total maintenance 100mg/day; (<45kg): initially 7.5–15mg daily in 2–3 divided doses, may increase daily by 2.5–5mg increments, divided in up to 5 doses; max single dose: 15mg; max total maintenance 50mg/day. Hepatic or renal impairment (CrCl 15–90mL/min), NAT2 poor metabolizers: (≥45kg): initially 15mg daily in divided doses; (<45kg): initially 7.5mg daily in divided doses.
RUZURGI Contraindications:
History of seizures.
RUZURGI Warnings/Precautions:
Consider dose reduction or discontinuation if seizure occurs. Discontinue and treat if anaphylaxis occurs. Hepatic or renal impairment: monitor; adjust dose or discontinue as needed. N-acetyltransferase 2 (NAT2) poor metabolizers. Pregnancy. Nursing mothers.
RUZURGI Classification:
Potassium channel blocker.
RUZURGI Interactions:
Concomitant drugs that lower seizure threshold may increase seizure risk. Additive effects when concomitant drugs with cholinergic effects (eg, direct or indirect cholinesterase inhibitors).
Adverse Reactions:
Paresthesia/dysesthesia, abdominal pain, dyspepsia, dizziness, nausea; seizures, hypersensitivity.
Generic Drug Availability:
NO
How Supplied:
Tabs—100
